-
公开(公告)号：SMT201400124B
公开(公告)日：2014-11-10
申请号：SM201400124
申请日：2014-09-05
Applicant: VERTEX PHARMA
Inventor： BOTFIELD MARTYN , FANNING LEV T D , BINCH HAYLEY , SHETH URVI , SILINA ALINA , YANG XIAOQING , GROOTENHUIS PETER D J , GOOR FREDRICK VAN , NUMA MEHDI MICHEL DJAMEL , AURLEY DENNIS
Abstract: The present invention relates to modulators of cystic fibrosis transmembrane conductance regulator (“CFTR”), compositions thereof, and methods therewith. The present invention also relates to methods of treating diseases using modulators of CFTR.
-
公开(公告)号：SI2349263T1
公开(公告)日：2014-09-30
申请号：SI200930982
申请日：2009-10-23
Applicant: VERTEX PHARMA
Inventor： BINCH HAYLEY , FANNING LEV T D , HURLEY DENNIS , SHETH URVI , SILINA ALINA , YANG XIAOQING , BOTFIELD MARTYN , GROOTENHUIS PETER D J , VAN GOOR FREDRICK , NUMA MEHDI MICHEL DJAMEL
IPC: A61K31/00 , C07D453/00 , C12Q1/00
-
公开(公告)号：DK2349263T3
公开(公告)日：2014-07-21
申请号：DK09822784
申请日：2009-10-23
Applicant: VERTEX PHARMA
Inventor： BINCH HAYLEY , FANNING LEV T D , HURLEY DENNIS , SHETH URVI , YANG XIAOQING , BOTFIELD MARTYN , GROOTENHUIS PETER D J , VAN GOOR FREDRICK , NUMA MEHDI MICHEL DJAMEL , SILINA ALINA
IPC: A61K31/439 , C07D453/04 , C12Q1/02
-
公开(公告)号：SI2358680T1
公开(公告)日：2013-08-30
申请号：SI200930620
申请日：2009-10-23
Applicant: VERTEX PHARMA
Inventor： ZHANG BEILI , KRAWIEC MARIUSZ , BOTFIELD MARTYN , GROOTENHUIS PETER D J , VAN GOOR FREDRICK
IPC: C07D215/00 , A61K31/00 , A61P1/00 , A61P11/00
-
公开(公告)号：UA102261C2
公开(公告)日：2013-06-25
申请号：UAA201102840
申请日：2009-08-13
Applicant: VERTEX PHARMA
-
Patent Agency Ranking
公开(公告)号：DK2358680T3
公开(公告)日：2013-06-24
申请号：DK09744286
申请日：2009-10-23
Applicant: VERTEX PHARMA
Inventor： ZHANG BEILI , KRAWIEC MARIUSZ , BOTFIELD MARTYN , GROOTENHUIS PETER D J , VAN GOOR FREDRICK
IPC: C07D215/56 , A61K31/4704 , A61P1/00 , A61P11/00
-
公开(公告)号：NZ573052A
公开(公告)日：2012-03-30
申请号：NZ57305207
申请日：2007-04-25
Applicant: VERTEX PHARMA
Inventor： RAMACHANDRAN RAVI K , HARDING MATTHEW W , CARON PAUL R , BOTFIELD MARTYN , HARE BRIAN J , BANDARU RAJ , KELLIHER KEVIN M , CORNELL CATHARINE N
Abstract: Disclosed is a method of evaluating a subject, the method comprising: determining the expression levels of the genes in a signature set of genes in the subject, wherein the signature set of genes comprises one or more interferon-sensitive genes(ISG) selected from the group consisting of IFIT1, RSAD2, IFIT2, IFIT6, IFI44, IFIT5, PLSCR1, IFIT3, IFI35, IFITM1, IFITM3, IFI30, IFITM2, GIP2, OAS3, MX1, IFIL44L, IFI27, IFIT2A, PRSAD, or IFITA, wherein the signature set has the following properties: it includes a plurality of genes each of which is differentially expressed as between virally infected individuals and non-infected individuals, and the differential expression is predictive of infection with no more than about 15% false positives; and comparing the expression level of each of the genes in the set from the subject with a reference value, thereby evaluating the subject, wherein the reference value is either: (i) a non-infected reference and wherein differential expression of each of the genes in the signature set of genes indicates a first state, and differential expression of less than all of the genes in the signature set indicates a second state; or (ii) an infected reference and wherein non-differential expression of each of the genes in the signature set of genes indicates a first state, and non-differential expression of less than all of the genes in the signature set indicates a second state, wherein the evaluating occurs prior to, during the course of, or after administering an inhibitor of a viral protease to the subject, and wherein the evaluation of the expression of the genes in a signature set of genes is performed on an isolated sample from the subject.
-
公开(公告)号：SG178337A1
公开(公告)日：2012-03-29
申请号：SG2012009080
申请日：2010-02-18
Applicant: VERTEX PHARMA
Inventor： ROWE WILLIAM , HURTER PATRICIA , YOUNG CHRISTOPHER R , DINEHART KIRK , VERWIJS MARINUS JACOBUS , OVERHOFF KIRK , GROOTENHUIS PETER D J , BOTFIELD MARTYN , GROSSI ALFREDO , ZLOKARNIK GREGOR , VAN GOOR FREDRICK F
Abstract: The present invention relates to pharmaceutical compositions comprising a solid dispersion of N-[2,4-Bis( 1, 1 -dimethylethyl)-5-hydroxyphenyl]- 1,4-dihydro-4-oxoquinoline-3-carboxamide, methods of manufacturing pharmaceutical compositions of the present invention, and methods of administering pharmaceutical compositions of the present invention.
-
公开(公告)号：MX2011001782A
公开(公告)日：2012-02-08
申请号：MX2011001782
申请日：2009-08-13
Applicant: VERTEX PHARMA
Inventor： YOUNG CHRISTOPHER , GROSSI ALFREDO , ROWE WILLIAM , HURTER PATRICIA , DINEHART KIRK , OVERHOFF KIRK , GROOTENHUIS PETER D , BOTFIELD MARTYN , VERWIJS MARINUS JACOBUS
IPC: A61K47/32
Abstract: La presente invención se refiere a una composición farmacéutica que comprende una dispersión sólida de N-[2,4-Bis(1,1-dimetiletil) -5-hidroxifenil]-1,4-dihidro-4-oxoquinoline-3-carboxamido, métodos de manufactura de composiciones farmacéuticas de la presente invención y métodos de administración de composición farmacéutica de la presente invención.
-
公开(公告)号：CA2741718A1
公开(公告)日：2010-04-29
申请号：CA2741718
申请日：2009-10-23
Applicant: VERTEX PHARMA
Inventor： BINCH HAYLEY , FANNING LEV T D , HURLEY DENNIS , SHETH URVI , SILINA ALINA , YANG XIAOQING , BOTFIELD MARTYN , GROOTENHUIS PETER D J , VAN GOOR FREDRICK , NUMA MEHDI MICHEL DJAMEL
IPC: C07D471/12 , A61K31/4709 , A61P11/00 , C07D451/02 , C12Q1/02
Abstract: The present invention relates to modulators of cystic fibrosis transmembrane conductance regulator ("CFTR"), compositions thereof, and methods therewith. The present invention also relates to methods of treating diseases using modulators of CFTR. (l); or pharmaceutically acceptable salts thereof, wherein: ring A is selected from:
-
-
-
-
-
-
-
-
-
Search Results
101
records
(took 0.022 seconds)
